This guide walks through the full TRIUMPH program, the TRIUMPH-4 dataset, the 2026 readouts still to come, how retatrutide stacks up against tirzepatide and semaglutide on published trial data, and what the regulatory picture realistically looks like from here
Kosiborod MN, Esterline R, Furtado RHM et al (2021) Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
Why inflammation and metabolic health are tightly linked A lot of patients think of inflammation as a separate problem, but in metabolic medicine it is often part of the same process
For cash-pay patients on compounded semaglutide, TrimRx runs roughly $2,388 per year at the $199 entry rate
Think of it as giving your body the best possible conditions to repair while BPC-157 removes the bottlenecks